MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Sarepta Therapeutics Inc

Затворен

СекторЗдравеопазване

14 -36.19

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

12.8

Максимум

19.16

Ключови измерители

By Trading Economics

Приходи

-607M

-448M

Продажби

86M

745M

P/E

Средно за сектора

27.205

39.857

Марж на печалбата

-60.08

Служители

1,372

EBITDA

-560M

-369M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+173.44% upside

Дивиденти

By Dow Jones

Следващи печалби

6.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-8.5B

1.9B

Предишно отваряне

50.19

Предишно затваряне

14

Настроения в новините

By Acuity

67%

33%

328 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Sarepta Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.03.2025 г., 14:19 ч. UTC

Значими двигатели на пазара

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

17.07.2025 г., 16:44 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Lucid, TSMC, Elevance, Sarepta, PepsiCo, Abbott Labs, Archer Daniels, and More -- Barrons.com

17.07.2025 г., 13:48 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Lucid, TSMC, United, Sarepta, PepsiCo, Abbott Labs, MP Materials, Archer Daniels, and More -- Barrons.com

17.07.2025 г., 10:57 ч. UTC

Печалби

These Stocks Are Moving the Most Today: TSMC, United Airlines, Sarepta, PepsiCo, GE Aerospace, MP Materials, Archer Daniels, and More -- Barrons.com

17.07.2025 г., 09:08 ч. UTC

Горещи акции

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

17.06.2025 г., 09:10 ч. UTC

Горещи акции

Stocks to Watch Tuesday: SunRun, Enphase Energy, Mitsubishi, Roku -- WSJ

17.06.2025 г., 08:59 ч. UTC

Горещи акции

Stocks to Watch Tuesday: Sunrun, Enphase Energy, Mitsubishi, Roku -- WSJ

16.06.2025 г., 08:55 ч. UTC

Горещи акции

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Sarepta Therapeutics Inc Прогноза

Ценова цел

By TipRanks

173.44% нагоре

12-месечна прогноза

Среден 38.5 USD  173.44%

Висок 98 USD

Нисък 9 USD

Според 26 анализатори от Wall Street, предложили 12-месечна ценова цел за Sarepta Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

26 ratings

9

Купи

15

Задържане

2

Продай

Техническа оценка

By Trading Central

N/A / 62.47Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

328 / 376 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.